Home » ELAN REAFFIRMS TYSABRI COMMITMENT
ELAN REAFFIRMS TYSABRI COMMITMENT
Pharmaceutical company Elan has forecast a ⁈150m-⁈175m full-year before-tax loss, excluding revenues from its suspended MS drug Tysabri..Revenue for the first three months of the year was $134.3m (⁈106m), ahead of analysts' forecasts of $127.1m (⁈100m).
Ireland On-Line
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May